Vestcor Inc Has $821,000 Holdings in Lantheus Holdings, Inc. $LNTH

Vestcor Inc trimmed its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 31.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 12,334 shares of the medical equipment provider’s stock after selling 5,705 shares during the period. Vestcor Inc’s holdings in Lantheus were worth $821,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of LNTH. M&T Bank Corp bought a new position in shares of Lantheus during the 4th quarter worth approximately $370,950,000. Norges Bank bought a new position in shares of Lantheus during the 4th quarter worth approximately $76,197,000. Hotchkis & Wiley Capital Management LLC bought a new position in shares of Lantheus during the 3rd quarter worth approximately $11,443,000. Reinhart Partners LLC. boosted its holdings in shares of Lantheus by 15.9% during the 4th quarter. Reinhart Partners LLC. now owns 1,562,576 shares of the medical equipment provider’s stock worth $103,990,000 after buying an additional 214,820 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Lantheus by 73.4% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 448,452 shares of the medical equipment provider’s stock worth $23,001,000 after buying an additional 189,814 shares in the last quarter. 99.06% of the stock is currently owned by institutional investors.

Lantheus Price Performance

Shares of LNTH opened at $100.01 on Tuesday. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $104.00. The business’s fifty day moving average is $88.48 and its 200 day moving average is $75.44. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The stock has a market cap of $6.51 billion, a P/E ratio of 24.10 and a beta of -0.03.

Lantheus (NASDAQ:LNTH) last issued its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The company had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. During the same period last year, the business earned $1.53 EPS. Lantheus’s quarterly revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 4.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

LNTH has been the topic of a number of research analyst reports. Mizuho increased their price target on Lantheus from $100.00 to $115.00 and gave the stock an “outperform” rating in a report on Wednesday, May 27th. Jefferies Financial Group restated a “buy” rating and set a $110.00 price target on shares of Lantheus in a report on Tuesday, March 17th. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a report on Friday, February 27th. Citizens Jmp increased their price target on Lantheus from $85.00 to $115.00 and gave the stock a “market outperform” rating in a report on Friday, May 8th. Finally, Citigroup restated an “outperform” rating on shares of Lantheus in a report on Friday, May 8th. Eight investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus target price of $101.86.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.